London
· Delayed Price · Currency is GBP · Price in EURLaboratorios Farmaceuticos Rovi Company Description
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas.
Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi.
It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets.
Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain.
Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
| Country | Spain |
| Founded | 1946 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 2,111 |
| CEO | Juan Lopez-Belmonte Encina |
Contact Details
Address: Calle JosE Isbert, 2 Madrid, 28223 Spain | |
| Phone | 34 91 021 30 00 |
| Website | rovi.es |
Stock Details
| Ticker Symbol | 0ILL |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | ES0157261019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Juan Lopez-Belmonte Encina | Chief Executive Officer |
| Javier Lopez-Belmonte Encina | Chief Financial Officer |
| Marta Martínez | Head of Investor Relations |